Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Methotrexate plus dupilumab for Meniere's disease (pilot)
ChiCTR2400087114Phase 4Not yet recruiting
- Sponsor
- Shandong Second Provincial General Hospital
- Start
- Jul 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of methotrexate and dupilumab in Meniere Disease, sponsored by Shandong Second Provincial General Hospital. Primary endpoints: Safety and Number of vertigo episodes in 3 months. Planned start Jul 2024; status: not yet recruiting.
02
Drugs
methotrexatedupilumab
03
Conditions
Meniere Disease
Beyond the preview
Go deeper on ChiCTR2400087114.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400087114.